Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

PLASMIDSAURUS INC.

UEI: NR53EBKXAY99CAGE: 99QE9

PLASMIDSAURUS INC. is a federal contractor, registered under UEI NR53EBKXAY99 and CAGE code 99QE9. It has been awarded $38,405 in federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

NR53EBKXAY99

CAGE Code

99QE9

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

PlasmidSaurus Inc. specializes in research and development in biotechnology, focusing on molecular biology platforms and genetic engineering systems that support advanced therapeutic and diagnostic applications. Their technical expertise lies in plasmid vector design, gene expression optimization, a...

PlasmidSaurus Inc. specializes in research and development in biotechnology, focusing on molecular biology platforms and genetic engineering systems that support advanced therapeutic and diagnostic applications. Their technical expertise lies in plasmid vector design, gene expression optimization, and recombinant protein production pipelines, with a clear emphasis on non-nanobiotechnology applications. The company demonstrates proficiency in translational biotech workflows, including cloning strategies, microbial and eukaryotic expression systems, and downstream purification protocols tailored for government-funded biomedical innovation. Their work suggests a strong foundation in laboratory automation, quality control for biological materials, and compliance with Good Laboratory Practices, positioning them as a niche provider of foundational biotech R&D services for defense and public health initiatives. The contractor has delivered services to the Department of Defense, indicating engagement in defense-relevant biotechnology programs such as biothreat detection, vaccine platform development, or countermeasure manufacturing. Their relationship with DoD suggests alignment with programs under the Defense Health Agency, DARPA, or the U.S. Army Medical Research and Development Command, where rapid, scalable biomanufacturing and genetic tool development are critical. PlasmidSaurus operates exclusively within NAICS 541714, which defines their market as non-nanotech biotech R&D—encompassing gene synthesis, recombinant DNA technology, and cellular engineering for biomedical applications. They are not engaged in broader pharmaceutical development or clinical trials, but rather in the upstream engineering of biological systems that enable downstream therapeutics and diagnostics. As a small business structured as a 2L entity based in Arcadia, California, PlasmidSaurus Inc. maintains a lean, specialized operational model. The company holds no federal certifications, relying instead on technical precision and domain-specific expertise to compete in the federal biotech R&D market. Their geographic location places them within a high-concentration biotech corridor, facilitating access to academic partnerships and specialized laboratory infrastructure.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

4

All time

Active

1

Currently performing

Completed

3

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with PLASMIDSAURUS INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for PLASMIDSAURUS INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in PLASMIDSAURUS INC.'s top NAICS codes and agencies

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

about 14 hours ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # 75N98027Q00090
The National Institutes of Health (NIH) is soliciting a Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for high-throughput DNA sequencing services, including Sanger DNA sequencing and whole-plasmid sequencing. The scope of work involves processing plasmid DNA, genomic DNA, and PCR-generated material, with requirements for PCR amplification, product purification, and DNA normalization. The contractor is responsible for providing all sample collection and shipping materials, maintaining strict confidentiality of sequencing data, and retaining DNA samples for at least 180 days post-sequencing. Deliverables include specific electronic file formats such as .ab1, .fasta, and raw FASTQ data, alongside a Monthly Status Report submitted to the Contracting Officer's Representative (COR). The contract spans a five-year period from January 4, 2027, to January 3, 2032, with a total estimated value ranging from $184,200.00 to $958,584.20. Performance and delivery are centered at the NIEHS facility in Research Triangle Park, North Carolina. Award selection will be based on a best value tradeoff, where technical capability and past performance are weighted more heavily than price. Technical evaluations will focus on sequencing capability, personnel qualifications, quality assurance/control, and data management. The acquisition is not set aside for small businesses and falls under NAICS code 541714.
National Institutes Of Health Olao

POSTED

about 14 hours ago

DEADLINE

in 19 days
View Details
NAICS: 541714
New
Federal
FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Solicitation # FDABAA-27-00123
The FY27 FDA Broad Agency Announcement (FDABAA-27-00123) solicits basic and applied research and development proposals to advance regulatory science and innovation. Managed by the FDA Office of Acquisitions and Grants Services, this solicitation is open to all responsible sources, including small businesses and academic institutions. The program focuses on 22 priority research areas, with recent updates adding specific interests in human tooth enamel evaluation techniques for anticaries dentifrice products and the adoption of Super Intelligence terminology in tobacco and nicotine research per Executive Order 14434. Interested parties must follow a two-tiered submission process consisting of a three-page concept paper and a comprehensive full proposal, which includes a technical volume limited to 50 pages and a detailed cost proposal. All applications must be submitted as searchable PDFs via email by January 22, 2027, at 5:00 PM EST. A virtual BAA Day is scheduled for December 8, 2026, to provide guidance on the application process and FDA priorities. Awards are based on the overall best value to the government, evaluated through a high-level relevance review followed by a technical review by subject matter experts. Successful offerors must comply with Good Manufacturing Practice Regulations (21 CFR Parts 210-211) and other relevant biological or diagnostic standards. Additionally, proposals exceeding $900,000 from non-small businesses require a Small Business Subcontracting Plan. Contractors must also warrant the absence of organizational conflicts of interest and adhere to strict data disclosure and privacy regulations.
FDA Office Of Acq Grant Svcs

POSTED

about 14 hours ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Federal
Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)
Solicitation # Presolicitation_NOI_Sole_Source_EPL
The U.S. Environmental Protection Agency, through the Office of the Chief Procurement Officer's Water, Tribal, and Science Division, intends to award a firm-fixed price purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The work will be performed at the EPA Headquarters in Washington, DC, and focuses on the toxicologic pathology of environmental contaminants, including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. This acquisition is intended to continue existing larger studies to maintain data integrity and avoid protocol deviations. The EPA intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with environmental contaminants, compliance with Good Laboratory Practice regulations, and their ability to accept hand-delivered samples as a local vendor. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. While the agency intends to award to EPL, other responsible sources may submit capability statements, proposals, or quotations by November 30, 2026. The estimated award date is December 3, 2026. All vendors must maintain a public profile in the System for Award Management and utilize the FedConnect portal for contract communications.
Tribal & Science Division Water

POSTED

5 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

5 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Federal
Laguna Industry Day
Solicitation # DARPA-SN-27-18
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is hosting a virtual Industry Day on December 9, 2026, for the Laguna program under Special Notice DARPA-SN-27-18. The program's primary objective is to develop and demonstrate integrated manufacturing approaches that convert abundant domestic feedstocks, such as sugars, ethylene, and BTX, into application-ready specialty chemical formulations. By minimizing intermediate processing steps and separations, the initiative seeks to reduce reliance on vulnerable foreign supply chains. The anticipated 36-month effort is divided into two technical areas: Make and Formulate, which focuses on developing defense-relevant specialty products from U.S. raw materials, and Model, which aims to create predictive tools to optimize the relationship between feedstocks, synthesis, and final product performance. This notice is issued for information and program planning purposes and does not constitute a formal solicitation for proposals. Interested parties must register for the Industry Day event by December 2, 2026. The program requires that resulting products meet or exceed the performance of current military materials, with deliverables including technoeconomic analyses, life cycle assessments, and commercialization strategy plans. Technical and administrative inquiries are managed by Dr. William Mounfield and can be directed to [email hidden]. A draft program solicitation is expected to be released on sam.gov prior to the Industry Day event.
Defense Advanced Research Projects Agcy

POSTED

6 days ago

DEADLINE

in 15 days
View Details
NAICS: 541330
New
Federal
AIR FORCE CRYPTOLOGIC OFFICE COMMERCIAL SOLUTIONS OPENING
Solicitation # FA7037-21-S-C001
The Air Force Cryptologic Office (AFCO) Cyberspace Intelligence Surveillance and Reconnaissance and Multi-Domain Innovation Division is soliciting innovative commercial capabilities through Commercial Solutions Opening FA7037-21-S-C001. The agency seeks mature technologies and services in Electromagnetic Warfare, Information Operations, and electromagnetic digital communications, with a specific goal of achieving a field demonstration within one year. All acquisitions under this solicitation are treated as commercial items and are governed by 10 USC 3458 and DFARS 212.70. Awards may be issued as traditional contracts or Other Transactions under 10 U.S.C. 2371b, with estimated funding ranging from 50,000 to 50,000,000 dollars over a period of performance typically lasting between one and five years. The procurement utilizes a competitive two-phase submission process. Phase I requires the submission of Quad Charts and White Papers, which are evaluated based on technical merit, importance to the AFCO mission, and fund availability via peer or scientific review. Selected offerors are then invited to Phase II to submit full technical and price proposals, including a separate Statement of Work. The project structure is designed with base period tasks to demonstrate technology feasibility, followed by option tasks for design, fabrication, testing, and evaluation. Due to the nature of the work, offerors must possess the necessary personnel and facility security clearances to handle classified information in accordance with the National Industrial Security Program Operating Manual.
Department Of Defense

POSTED

6 days ago

DEADLINE

in 11 months
View Details
NAICS: 541330
Federal
Army Contracting Command – Red River Army Depot (ACC-RRAD) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911RQ-27-S-C001
The Army Contracting Command – Red River Army Depot (ACC-RRAD) has issued solicitation W911RQ-27-S-C001, a Commercial Solutions Opening (CSO) aimed at modernizing the Organic Industrial Base (OIB). This initiative focuses on Convergent Manufacturing, integrating technologies such as digital twins, automation, cyber security, and connected digital enterprises to enhance the Defense Manufacturing Base. The CSO utilizes a streamlined acquisition process authorized by DFARS Subpart 212-70 and FAR Part 12, allowing the government to competitively procure innovative commercial items, technologies, and services from both traditional and non-traditional defense contractors. The overall solicitation remains open until September 30, 2027, with a general period of performance for individual awards typically not exceeding 12 months. The procurement is executed through specific Areas of Interest (AoIs), which have included diverse requirements such as the procurement of micro trucks, the replacement of fire suppression systems in Building 431, the installation of office cubicles, and the lease and maintenance of industrial parts washers. Evaluation occurs in three phases: an initial solution brief, a presentation or pitch, and a final Commercial Solutions Proposal (CSP). Technical proposals are evaluated on responsiveness, merit, and innovation, while price proposals must be determined as fair and reasonable. Awardees must be registered in the System for Award Management (SAM) and possess a Unique Entity ID (UEI). Specific projects may require additional certifications, such as Texas fire protection engineering licenses or environmental impairment liability insurance of up to 10 million dollars aggregate.
Department Of Defense

POSTED

8 days ago

DEADLINE

in 11 months
View Details